aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
aTyr Pharma (LIFE) Tops Q3 EPS by 6c
November 12, 2020 4:38 PM ESTaTyr Pharma (NASDAQ: LIFE) reported Q3 EPS of ($0.68), $0.06 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $148 thousand versus the consensus estimate of $100 thousand.
Throughout the third quarter, we remained focused on our clinical program for our lead therapeutic candidate, ATYR1923. We now... More
